Award
National Institute of Allergy and Infectious Diseases 5R01AI184416-02
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
Recipient
National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH
Award Amount
$464,199.00
Ceiling
$464,199.00
Awarded
December 09, 2025
Identifier
5R01AI184416-02
NIH awarded a project to study therapeutic drug monitoring of linezolid in rifampin-resistant tuberculosis patients through a randomized controlled trial to assess efficacy and safety.
Description
This NIH-funded project aims to evaluate the efficacy of therapeutic drug monitoring of linezolid to prevent toxicity in patients with rifampin-resistant tuberculosis in South Africa. The project involves a randomized controlled trial with a focus on pharmacokinetics, toxicity, and treatment outcomes.